Sonoma Pharmaceuticals (NASDAQ:SNOA) was upgraded by ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
Other equities analysts also recently issued research reports about the company. Zacks Investment Research upgraded Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a report on Wednesday, January 10th. Maxim Group reiterated a “buy” rating and set a $7.00 price target (down previously from $11.00) on shares of Sonoma Pharmaceuticals in a report on Wednesday, February 14th.
Shares of SNOA stock opened at $3.76 on Wednesday. Sonoma Pharmaceuticals has a 12 month low of $3.50 and a 12 month high of $7.75. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.83 and a current ratio of 4.62. The company has a market cap of $17.83, a price-to-earnings ratio of -1.85 and a beta of 1.18.
Sonoma Pharmaceuticals (NASDAQ:SNOA) last announced its quarterly earnings results on Wednesday, February 7th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.63) by ($0.10). Sonoma Pharmaceuticals had a negative net margin of 70.46% and a negative return on equity of 70.95%. The company had revenue of $4.84 million for the quarter, compared to analyst estimates of $4.50 million. sell-side analysts anticipate that Sonoma Pharmaceuticals will post -2.86 earnings per share for the current fiscal year.
An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Deutsche Bank AG purchased a new stake in shares of Sonoma Pharmaceuticals (NASDAQ:SNOA) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 25,141 shares of the company’s stock, valued at approximately $137,000. Deutsche Bank AG owned about 0.54% of Sonoma Pharmaceuticals as of its most recent SEC filing. 13.24% of the stock is currently owned by hedge funds and other institutional investors.
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and markets solutions for the treatment of dermatological conditions and advanced tissue care in the United States, Latin America, Europe, and internationally. The company offers Microcyn line of products that are based on electrically charged oxychlorine small molecules designed to target a range of pathogens, such as viruses, fungi, and spores, as well as bacteria, including antibiotic-resistant strains.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.